Every 8-K that Liquidia Corporation (LQDA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LQDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LQDA filings page.
Liquidia Corporation (LQDA) reports that the U.S. Food and Drug Administration has granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for treating Raynaud's phenomenon associated with systemic sclerosis (SSc-RP), a serious, high-mortality autoimmune disease with no FDA-approved therapy specifically for SSc-RP.
Liquidia plans to start the RE-WARM Phase 2a study in October 2026 in about 75 adults with SSc experiencing symptomatic Raynaud's attacks, across up to 30 U.S. sites, with primary completion targeted for February 2027. YUTREPIA is already approved for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease but not for SSc-RP.
Liquidia Corporation reported a strong turnaround for the quarter ended June 30, 2026, driven by the commercial launch of YUTREPIA. Total revenue was $171.7 million, up sharply from $8.8 million a year earlier, primarily from YUTREPIA product sales.
The company generated net income of $74.7 million and non-GAAP Adjusted EBITDA of $96.3 million, marking a fourth consecutive quarter of increasing profitability. Cash and cash equivalents rose to $284.2 million as of June 30, 2026, compared with $190.7 million at December 31, 2025, while total stockholders’ equity increased to $195.1 million.
Research and development expenses grew to $17.2 million, reflecting higher investment in the L606 program and YUTREPIA-related activities, and selling, general and administrative expenses increased to $57.4 million to support commercialization. The company notes that maintaining YUTREPIA’s approval and ongoing commercialization remains subject to patent litigation in which an opposing party is seeking injunctive relief that could halt sales.
Liquidia Corporation reported results from its annual stockholders meeting. Shareholders elected three Class II directors to serve until the 2029 annual meeting, with David Johnson receiving 44,874,399 votes for, 58,179 withheld, and 22,546,609 broker non-votes.
Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 67,279,878 votes for, 183,739 against, and 15,570 abstentions. In a non-binding advisory vote, shareholders approved compensation for the named executive officers with 44,270,299 votes for, 612,749 against, 49,530 abstentions, and 22,546,609 broker non-votes. A quorum was present, with 67,479,187 of 88,893,621 eligible shares represented.
Liquidia Corporation filed a report to share that it will be added to the S&P SmallCap 600® Index, effective before the market opens on June 22, 2026. The company highlights this as a milestone reflecting its market capitalization, liquidity, publicly traded float and profitability profile.
Liquidia develops therapies for challenging respiratory and vascular diseases using its PRINT® technology, including YUTREPIA® (treprostinil) inhalation powder, the investigational L606 formulation and a marketed generic Treprostinil Injection. The company notes that forward-looking statements about visibility, strategy and long-term value are subject to risks described in its SEC filings.
Liquidia Corporation reported a sharp turnaround in first quarter 2026 results driven by YUTREPIA sales. Total revenue reached $132.9 million for the three months ended March 31, 2026, up from $3.1 million a year earlier, as product sales grew to $129.9 million from zero following YUTREPIA’s 2025 U.S. launch.
The company generated net income of $52.9 million, or $0.60 per basic share and $0.52 per diluted share, compared with a net loss of $38.4 million in the prior-year quarter. Adjusted EBITDA was $71.2 million. Cash and cash equivalents increased to $222.8 million as of March 31, 2026, from $190.7 million as of December 31, 2025, while Liquidia continued to invest in R&D and commercialization and highlighted ongoing patent litigation that could affect YUTREPIA’s commercialization.
Liquidia Corporation reported a transformative 2025 driven by the U.S. launch of YUTREPIA. Product sales, net, reached $148.3 million for the year, contributing to total revenue of $158.3 million compared with $14.0 million in 2024. In fourth quarter 2025 the company generated net income of $14.6 million and non-GAAP adjusted EBITDA of $27.3 million, marking a second consecutive profitable quarter.
For full year 2025, Liquidia recorded a net loss of $68.9 million, an improvement from a $128.3 million loss in 2024. Cash and cash equivalents were $190.7 million as of December 31, 2025, up from $176.5 million a year earlier, while total assets increased to $327.9 million. Research and development expenses fell 18% to $39.3 million, as efforts shifted toward commercialization, while selling, general and administrative expenses nearly doubled to $157.2 million to support the YUTREPIA launch and related legal costs.
Liquidia Corporation filed a current report stating that it has issued a press release with its preliminary financial results for the quarter ended December 31, 2025 and a corporate update. The company furnished this press release as Exhibit 99.1 to the filing, indicating that the details are provided for informational purposes and are not deemed filed under certain liability provisions of the securities laws.
Liquidia Corporation furnished a Current Report announcing it issued a press release with financial results for the quarter ended September 30, 2025, and provided a corporate update.
The press release is included as Exhibit 99.1. The information under Item 2.02 is expressly stated as furnished and not deemed filed under the Exchange Act.
Liquidia Corporation entered an exclusive license with Vectura Limited to develop, manufacture and commercialize in the United States treprostinil products, including Liquidia’s L606, administered via Vectura’s nebulizer device for PAH and PH‑ILD. Vectura will manufacture and supply clinical and commercial devices.
Financial terms include an upfront $2,000,000 payment, development milestones of up to $12,000,000, sales milestones of up to $92.5 million, and royalties at middle single‑digit rates on U.S. sales. Liquidia also secured rights of first negotiation for additional territories and indications. The agreement continues on a country‑ and product‑specific basis through the applicable royalty term and includes customary termination rights for breach, bankruptcy, program discontinuation, feasibility determinations, related agreement terminations, effort requirements, and patent challenges.
Liquidia Corporation furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update. The press release is attached to the Form 8-K as Exhibit 99.1, and the filing includes an Inline XBRL cover page file as Exhibit 104.
The disclosure in Item 2.02 is furnished rather than filed and therefore is not deemed filed under Section 18 of the Exchange Act. No financial figures, operational details or transaction terms are included in this 8-K itself; the substantive results and update are contained in the referenced press release.
Liquidia Corporation (NASDAQ:LQDA) filed a Form 8-K to disclose the receipt of an additional USD 50 million under the Sixth Amendment to its Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. (HCR).
The funds became available after two key milestones satisfied the agreement’s “Funding Condition”:
- May 30 2025: The U.S. District Court for the Middle District of North Carolina denied United Therapeutics Corporation’s request for a preliminary injunction and temporary restraining order against Liquidia.
- June 2 2025: Liquidia completed its first commercial shipment of YUTREPIA™ (treprostinil inhalation powder) for treatment of PAH and PH-ILD.
The company now has access to a cumulative USD 100 million under the HCR facility (USD 50 million drawn in March plus the new USD 50 million). A further USD 25 million tranche remains available if: (1) YUTREPIA net sales exceed USD 100 million by June 30 2026 and (2) both parties mutually agree to fund.
No earnings data were provided, and the filing contains no new financial statements. The disclosure highlights strengthened liquidity to support YUTREPIA’s commercial rollout while acknowledging ongoing—but presently unsuccessful—litigation efforts by a competitor.
Liquidia Corporation (Nasdaq: LQDA) filed an 8-K to report the voting results of its June 17, 2025 Annual Meeting of Stockholders.
- Director elections: All three Class I nominees were elected to serve until the 2028 meeting. Roger A. Jeffs, Ph.D. received the highest support (46.1 M for; 0.1 M withheld), while Stephen Bloch, M.D. received 39.6 M for and 6.6 M withheld. Each proposal showed over 86% support when broker non-votes are excluded.
- Auditor ratification: Shareholders overwhelmingly ratified PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2025 (67.5 M for; 30 K against; 11 K abstain), representing 99.9% of votes cast.
- Say-on-pay: The non-binding advisory vote on named executive officer compensation passed with 44.4 M for (≈95%), 1.3 M against, and 0.5 M abstain.
- Quorum: 67.6 M shares (≈79% of the 85.4 M shares outstanding as of the April 23 record date) were present virtually or by proxy, satisfying quorum requirements.
No financial results, strategic transactions, or other material disclosures were included in this filing beyond routine corporate-governance matters.
Liquidia Corporation (Nasdaq: LQDA) disclosed in an 8-K that its wholly owned subsidiary, Liquidia Technologies, Inc., entered into an Indenture of Lease on 16 June 2025 with King Combs LLC for a new manufacturing facility in Morrisville, NC. The agreement covers 70,131 rentable square feet in Pathway Triangle Building 1 and runs from execution through 1 November 2036—a term of roughly 11 years and 5 months.
Key economic terms begin on the “Term Commencement Date” of 1 May 2026. Base rent will start at $260,069.13 per month (≈ $3.12 million annually) for the first 12-month period and will escalate 3.0 % each subsequent year. The company benefits from a six-month rent abatement after the commencement date but will assume responsibility for operating expenses thereafter.
The lease grants Liquidia (i) two 5-year extension options with 12-18 months’ notice and (ii) a one-time right of first offer on contiguous space, enhancing long-term flexibility. The filing states that the lease contains customary representations, warranties and covenants, and the full document will be filed with the forthcoming Form 10-Q for the quarter ending 30 June 2025.
For investors, the lease signals a significant capacity expansion ahead of expected commercial needs but also introduces a long-term fixed cost structure beginning in FY 2026.